Ira B Wilson1, Yunfeng Tie2, Mabel Padilla2, William H Rogers3,4, Linda Beer2. 1. Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island. 2. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. 4. Tufts Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Excellent adherence to HIV antiretroviral therapy (ART) remains a cornerstone of HIV care. A three-item adherence self-report scale was recently developed and validated, but the scale has not been previously tested in a nationally representative sample. DESIGN: We administered the adherence scale to participants in the Centers for Disease Control and Prevention's Medical Monitoring Project, which is a probability sample of US adults with diagnosed HIV. METHODS: We combined sociodemographic and clinical participant data from three consecutive cycles of the Medical Monitoring Project (6/2015-5/2018). We used medical record reviews to determine most recent viral load, and whether viral loads were suppressed at all measurement points in the past 12 months. We describe the relationship between adherence scale score and two measures of viral load suppression (most recent and sustained), and estimate linear regression models using sampling weights to determine independent predictors of ART adherence scores. RESULTS: Of those using ART, the median adherence score was 93 (100 = perfect adherence), and the standardized Cronbach's alpha was 0.83. For both measures of viral load suppression, the relationship with the adherence score was generally linear; there was no 'cutoff' point indicating good vs. poor adherence. In the multivariable model, younger age, nonwhite race, poverty, homelessness, depression, binge-drinking, and both non-IDU and IDU were independently associated with lower adherence. CONCLUSION: The adherence measure had good psychometric qualities and a linear relationship with viral load, supporting its use in both clinical care and research. Adherence interventions should focus on persons with the highest risk of poor adherence.
BACKGROUND: Excellent adherence to HIV antiretroviral therapy (ART) remains a cornerstone of HIV care. A three-item adherence self-report scale was recently developed and validated, but the scale has not been previously tested in a nationally representative sample. DESIGN: We administered the adherence scale to participants in the Centers for Disease Control and Prevention's Medical Monitoring Project, which is a probability sample of US adults with diagnosed HIV. METHODS: We combined sociodemographic and clinical participant data from three consecutive cycles of the Medical Monitoring Project (6/2015-5/2018). We used medical record reviews to determine most recent viral load, and whether viral loads were suppressed at all measurement points in the past 12 months. We describe the relationship between adherence scale score and two measures of viral load suppression (most recent and sustained), and estimate linear regression models using sampling weights to determine independent predictors of ART adherence scores. RESULTS: Of those using ART, the median adherence score was 93 (100 = perfect adherence), and the standardized Cronbach's alpha was 0.83. For both measures of viral load suppression, the relationship with the adherence score was generally linear; there was no 'cutoff' point indicating good vs. poor adherence. In the multivariable model, younger age, nonwhite race, poverty, homelessness, depression, binge-drinking, and both non-IDU and IDU were independently associated with lower adherence. CONCLUSION: The adherence measure had good psychometric qualities and a linear relationship with viral load, supporting its use in both clinical care and research. Adherence interventions should focus on persons with the highest risk of poor adherence.
Authors: Kathy K Byrd; John G Hou; Ron Hazen; Heather Kirkham; Sumihiro Suzuki; Patrick G Clay; Tim Bush; Nasima M Camp; Paul J Weidle; Ambrose Delpino Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.731
Authors: E G Bing; M A Burnam; D Longshore; J A Fleishman; C D Sherbourne; A S London; B J Turner; F Eggan; R Beckman; B Vitiello; S C Morton; M Orlando; S A Bozzette; L Ortiz-Barron; M Shapiro Journal: Arch Gen Psychiatry Date: 2001-08
Authors: Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: Ann Intern Med Date: 2018-08-21 Impact factor: 25.391
Authors: Kurt Kroenke; Tara W Strine; Robert L Spitzer; Janet B W Williams; Joyce T Berry; Ali H Mokdad Journal: J Affect Disord Date: 2008-08-27 Impact factor: 4.839
Authors: R L Cook; Z Zhou; N E Kelso-Chichetto; J Janelle; J P Morano; C Somboonwit; W Carter; G E Ibanez; N Ennis; C L Cook; R A Cohen; B Brumback; K Bryant Journal: Addict Sci Clin Pract Date: 2017-09-27
Authors: Sharoda Dasgupta; Yunfeng Tie; Linda Beer; Shacara Johnson Lyons; R Luke Shouse; Norma Harris Journal: Am J Public Health Date: 2022-06-02 Impact factor: 11.561